Stay updated on Tagraxofusp in Secondary AML Clinical Trial
Sign up to get notified when there's something new on the Tagraxofusp in Secondary AML Clinical Trial page.

Latest updates to the Tagraxofusp in Secondary AML Clinical Trial page
- Check2 days agoNo Change Detected
- Check9 days agoChange DetectedA new Revision: v3.6.4 entry was added and the previous Revision: v3.6.3 entry was removed in the study record history, indicating a small backend/UI update reflected in the log.SummaryDifference0.1%

- Check16 days agoNo Change Detected
- Check23 days agoChange DetectedThe history section now includes new entries for eligibility and study status, with a latest version noted as 27 around 2026-07-09 and an entry for 2026-07-10; an older entry from 2026-04-08 has been removed.SummaryDifference0.4%

- Check31 days agoChange DetectedRevision label updated to v3.6.3 in the page history, replacing the previous v3.6.2. This reflects a minor update to the page rendering or metadata for the study record, without changes to the study data.SummaryDifference0.1%

- Check38 days agoChange DetectedThe page history now shows Revision: v3.6.2, replacing the previous v3.6.0. This reflects an update to the record history’s versioning metadata.SummaryDifference0.1%

- Check52 days agoChange DetectedAdded Check who can join and Find Contact Information, plus a Revision: v3.6.0 note in the history view. These updates reflect UI and documentation changes that improve access to recruitment information and staff contact details, while recording the latest platform release.SummaryDifference0.4%

- Check59 days agoChange DetectedAn updated revision tag has been added to the history, changing from v3.5.4 to v3.5.5 to reflect an administrative update to the record. This change does not affect the study content or functionality, but records the latest version of the record in ClinicalTrials.gov history.SummaryDifference0.1%

Stay in the know with updates to Tagraxofusp in Secondary AML Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Tagraxofusp in Secondary AML Clinical Trial page.